Exelixis (EXEL)
NASDAQ:EXEL
Want to see EXEL full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.84Last Year’s EPS
0.75Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for CABOMETYX (double-digit global growth, notable TRx and market share gains), solid profitability and cash position, active share repurchases, and substantial advancement of ZANZA with one positive pivotal result (20% OS risk reduction in STELLAR-303 ITT) and multiple ongoing pivotal trials across tumor types. Offsetting these positives were increased gross-to-net deductions (30.2%), a materially higher tax provision, reliance on several upcoming readouts (some immature or timing‑sensitive), and broader development complexity highlighted by a competitive miss in a related triplet program. On balance, operational and commercial strengths and a broad, advancing pipeline materially outweigh the near-term execution and regulatory uncertainties.Company Guidance
Strong topline and cabozantinib franchise revenue growth
Total revenue of approximately $611 million in Q1 2026; U.S. cabo franchise net product revenues grew 8% year-over-year to $555 million; global cabo franchise net product revenues grew 12.5% year-over-year to $764 million. CABOMETYX net product revenues were $552.8 million (including $3.6 million in clinical trial sales).
Solid profitability and liquidity position
GAAP net income of ~$210.5 million (EPS $0.81 basic / $0.79 diluted) and non-GAAP net income of ~$232.8 million (EPS $0.90 basic / $0.87 diluted), excluding ~$22.3 million stock‑based compensation (net of tax). Cash and marketable securities of ~ $1.4 billion at 03/31/2026.
Commercial momentum and market share gains
CABOMETYX TRx volume grew 14% in Q1 2026 vs Q1 2025 while the oral TKI market basket grew 7% in the same period; CABOMETYX market share increased three percentage points from 44% to 47% (2025 to Q1 2026). Q1 had the highest number of new patient starts ever for CABOMETYX and the highest quarterly first-line RCC market share to date for CABOMETYX + nivolumab.
Aggressive capital return via share repurchases
Repurchased approximately $430.8 million of common stock in Q1 2026, retiring ~10 million shares at an average price of $42.99. $159.4 million remained under the prior $750 million repurchase plan and an additional $50 million buyback authorization was approved in May 2026.
ZANZA regulatory progress and broad pivotal program
NDA under review for ZANZA + atezolizumab in third-line-plus colorectal cancer (STELLAR-303); STELLAR-303 met one dual primary endpoint demonstrating a 20% reduction in risk of death in the ITT population. PDUFA date set for early December 2026. The ZANZA program includes seven ongoing or soon-to-start pivotal trials and multiple additional Phase II/III studies across CRC, RCC (including STELLAR-304 in non–clear cell RCC), NETs (STELLAR-311), meningioma (STELLAR-201 initiated), and other indications (STELLAR-316 adjuvant MRD trial planned midyear).
Clinical development momentum and enrollment
STELLAR-311 (ZANZA vs everolimus in NET) enrollment is pacing well and is ahead of initial projections; STELLAR-304 enrollment completed and top-line results expected in 2026 (second half). STELLAR-316 (MRD-positive resected stage 2/3 CRC) is on track to start around midyear, targeting a high‑risk ~20% MRD‑positive population.
Early-stage pipeline advancement
Four early clinical molecules (XL309, XB010, XB628, XB371) progressing in Phase 1, plus additional discovery-stage small molecule and ADC programs (including DLL3-targeted ADC XB773) being advanced to identify next franchise opportunities beyond cabo and ZANZA.
Operating expense control with modest sequential improvement
Total operating expenses of approximately $359 million in Q1 2026 versus $363 million in Q1 2025, reflecting lower clinical trial costs partially offset by higher FTE-related costs and stock-based compensation.
EXEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EXEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $48.70 | $46.21 | -5.11% |
Feb 10, 2026 | $42.98 | $42.94 | -0.09% |
Nov 04, 2025 | $37.90 | $40.37 | +6.52% |
Jul 28, 2025 | $44.39 | $36.94 | -16.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Exelixis (EXEL) report earnings?
Exelixis (EXEL) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Exelixis (EXEL) earnings time?
Exelixis (EXEL) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXEL EPS forecast?
EXEL EPS forecast for the fiscal quarter 2026 (Q2) is 0.84.